Literature DB >> 1658048

Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines.

E N Unemori1, M S Hibbs, E P Amento.   

Abstract

Synovial fibroblasts freshly isolated from the rheumatoid joint are characterized by their marked connective tissue degradative ability. This phenotype includes the ability to secrete large amounts of the matrix-degrading metalloproteinases, collagenase, and stromelysin. We have found that another aspect of this phenotype is the constitutive expression at both protein and mRNA levels of a 92-kD gelatinolytic metalloproteinase, which is not secreted by normal dermal or lung fibroblasts and is immunologically cross-reactive with a type V collagenase expressed by activated macrophages and neutrophils. Expression of this 92-kD metalloproteinase confers upon the fibroblasts the capacity to degrade collagenase- and stromelysin-resistant interstitial elements, such as collagen types IV, V and XI. In contrast to the 92-kD metalloproteinase, a 68-kD gelatinase (type IV collagenase) was expressed by all fibroblast types studied, indicating that its regulation is distinct from that of the 92-kD gelatinase. To identify what cytokines may be important in the induction of the rheumatoid synovial phenotype, including expression of the 92-kD gelatinase, we exposed normal dermal fibroblasts to a number of cytokines including many known or considered likely to be present in rheumatoid synovial fluid and tissue. Although IL-1 beta, tumor necrosis factor-alpha, lymphotoxin, platelet-derived growth factor, and basic fibroblast growth factor were capable of stimulating fibroblasts to secrete collagenase, only tumor necrosis factor-alpha, lymphotoxin, and IL-1 beta were able to induce expression of the 92-kD gelatinase, demonstrating discordant regulation of the two metalloproteinases. Expression of the 68-kD gelatinase was independent of that of the 92-kD gelatinase, as demonstrated at the protein and mRNA levels. Late passage rheumatoid synovial fibroblasts, which no longer constitutively expressed the 92-kD gelatinase, displayed an accentuated response to IL-1 beta when compared to normal dermal fibroblasts. Thus, in addition to IL-1 beta, tumor necrosis factor-alpha or lymphotoxin may contribute to the expression of a specific rheumatoid synovial phenotype in vivo that is associated with progressive matrix destruction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658048      PMCID: PMC295696          DOI: 10.1172/JCI115480

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Collagenase expression and endogenous activation in rabbit synovial fibroblasts stimulated by the calcium ionophore A23187.

Authors:  E N Unemori; Z Werb
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

2.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

Authors:  P A Guerne; B L Zuraw; J H Vaughan; D A Carson; M Lotz
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

3.  Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells.

Authors:  J M Dayer; B de Rochemonteix; B Burrus; S Demczuk; C A Dinarello
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells.

Authors:  J M Dayer; J Bréard; L Chess; S M Krane
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

5.  Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages.

Authors:  M S Hibbs; J R Hoidal; A H Kang
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

6.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

Authors:  T Saxne; M A Palladino; D Heinegård; N Talal; F A Wollheim
Journal:  Arthritis Rheum       Date:  1988-08

7.  Influences of gamma interferon on synovial fibroblast-like cells. Ia induction and inhibition of collagen synthesis.

Authors:  E P Amento; A K Bhan; K G McCullagh; S M Krane
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

8.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.

Authors:  B Beutler; D Greenwald; J D Hulmes; M Chang; Y C Pan; J Mathison; R Ulevitch; A Cerami
Journal:  Nature       Date:  1985 Aug 8-14       Impact factor: 49.962

9.  Active and latent forms of transforming growth factor beta activity in synovial effusions.

Authors:  R Fava; N Olsen; J Keski-Oja; H Moses; T Pincus
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.

Authors:  J M Dayer; B Beutler; A Cerami
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  30 in total

Review 1.  The paradox of matrix metalloproteinases in infectious disease.

Authors:  P T G Elkington; C M O'Kane; J S Friedland
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

2.  Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography.

Authors:  N J Peake; H E Foster; K Khawaja; T E Cawston; A D Rowan
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

3.  Multiple expression of matrix metalloproteinases in murine neurocysticercosis: Implications for leukocyte migration through multiple central nervous system barriers.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  Brain Res       Date:  2008-04-01       Impact factor: 3.252

4.  TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts.

Authors:  K Migita; K Eguchi; Y Kawabe; Y Ichinose; T Tsukada; T Aoyagi; H Nakamura; S Nagataki
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

5.  Cadherin-11 induces rheumatoid arthritis fibroblast-like synoviocytes to form lining layers in vitro.

Authors:  Hans P Kiener; David M Lee; Sandeep K Agarwal; Michael B Brenner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  Cultured human synovial fibroblasts rapidly metabolize kinins and neuropeptides.

Authors:  J M Bathon; D Proud; S Mizutani; P E Ward
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Comparative studies of collagenase and stromelysin-1 expression by rheumatoid synoviocytes in vitro.

Authors:  L C Tetlow; M Lees; D E Woolley
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Immunolocalization of basic fibroblast growth factor and platelet-derived growth factor-A during adjuvant arthritis in the Lewis rat.

Authors:  Z Qu; M Picou; T T Dang; E Angell; S R Planck; C E Hart; J T Rosenbaum
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo.

Authors:  L C Tetlow; M Lees; Y Ogata; H Nagase; D E Woolley
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

10.  Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis.

Authors:  Leonardo Lorente; María M Martín; Lorenzo Labarta; César Díaz; Jordi Solé-Violán; José Blanquer; Josune Orbe; José A Rodríguez; Alejandro Jiménez; Juan M Borreguero-León; Felipe Belmonte; Juan C Medina; Maria C Llimiñana; José M Ferrer-Agüero; José Ferreres; María L Mora; Santiago Lubillo; Manuel Sánchez; Ysamar Barrios; Antonio Sierra; José A Páramo
Journal:  Crit Care       Date:  2009-10-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.